OP0021 A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: Naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors